A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

Phase 3 Completed 73 enrolled Astellas Pharma Inc Astellas Pharma Taiwan, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.

Timeline

Start: 2007-12
Primary completion: 2010-04
Completion: 2010-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tacrolimus	Small molecule	—	Oral
Background	MMF	Unknown	—	Oral

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

Summary

Timeline

Drugs

Indications